The offer doesn't stop at Covid. Novartis opens up manufacturing ops to make Carisma’s CAR-M cell therapy
Novartis is doubling down on its contract manufacturing business.
The pharma giant lent a hand to Pfizer and BioNTech last year, deploying fill-finish sites in Switzerland and Slovenia to support large-scale production of their mRNA Covid-19 vaccine.
This time around, Novartis is reserving its cell and gene facility in Morris Plains, NJ for Carisma Therapeutics, whose HER2-targeted CAR-M cell therapy is being tested in initial trials for solid tumors.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,900+ biopharma pros reading Endpoints daily — and it's free.